Targeting multidrug resistance with small molecules for cancer therapy

Biomolecules and Therapeutics

Volumn 18, Issue 4, 2010, Pages 375-385

  Xia, Yan ^a   Lee, Kyeong ^a  

^a Dongguk University   (South Korea)

Author keywords

Atp binding cassette; Chemotherapy; Multidrug resistance

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BIRICODAR; CYCLOSPORIN A; DAUNORUBICIN; DIARYLIMIDAZOLE; DOXORUBICIN; DOXYCYCLINE; ELACRIDAR; ERYTHROMYCIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LANIQUIDAR; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; ONT 093; PACLITAXEL; QUININE; TARIQUIDAR; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZOSUQUIDAR;

BIOTRANSFORMATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; HYDROLYSIS; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; OVARY CANCER; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

EID: 78449234921     PISSN: 19769148     EISSN: None     Source Type: Journal    
DOI: 10.4062/biomolther.2010.18.4.375     Document Type: Review

References (73)

1. Abolhoda, A., Wilson, A. E., Ross, H., Denenberg, R. V., Burt, M. and Scotto, K. W. (1999). Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 5, 3352-3356.
2. Almquist, K. C., Loe, D. W., Hipfner, D. R., Mackie, J. E., Cole, S. P. and Deeley, R. G. (1995). Characterization of the M 190 000 multidrug resistance protein (MRP) in drug selected and transfected human tumor cell. Cancer Res. 55, 102-110.
3. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I. and Gottesman, M. M. (1999). Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 34, 361-398.
4. Anderle, P., Huang, Y. and Sadee, W. (2004). Intestinal membrane transport of drugs and nutrients: Genomics of membrane transporters using expression microarrays. Eur. J. Pharm. Sci. 21, 17-24.
5. Beck, J., Gekeler, V., Handgretinger, R. and Niethammer, D. (1994). PCR gene expression analysis of multidrug resistance associated genes in primary and relapsed state leukemias: comparison of mdrl, mrp, topoisomerase IIa, topoisomerase IIb and cyclin A mRNA levels. Proc. Am. Assoc. Cancer Res. 35, 337.
6. Benet, L. Z. and Cummins, C. L. (2001). The drug effluxmetabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 50(Suppl 1), S3-S11.
7. Borst, P., Evers, R., Kool, M. and Wijnholds, J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92, 1295-302.
8. Borst, P., Kool, M. and Evers, R. (1997). Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR. Cancer Biol. 8, 205-213.
9. Broxterman, H. J., Kuiper, C. M., Schuurhuis, G. J., Ossen-koppele, G. J., Feller, N., Scheper, R. J., Lankelma, J. and Pinedo, H. M. (1994). Analysis of P-glycoprotein (P-gp) and non-P-gp multidrug resistance in acute myeloid leukemia. Proc. Am. Assoc. Cancer Res. 35, 348.
10. Chearwae, W., Wu, C. P., Chu, H. Y., Lee, T. R., Ambudkar, S. V. and Limtrakul, P. (2006). Curcuminoids purified from tumeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother. Pharmacol. 57, 376-388.
11. Choi, C. H. (2005). ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5, 30.
12. Coburger, C., Wollmann, J., Baumert, C., Krug, M., Molnár, J., Lage, H. and Hilgeroth, A. (2008). Novel insight in structureactivity relationship and bioanalysis of P-Glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9-Diazatetraasteranes. J. Med. Chem. 51, 5871-5874.
13. Colabufo, N. A., Berardi, F., Cantore, M., Perrone, M. G., Contino, M., Inglese, C., Niso, M., Perrone, R., Azzariti, A., Simone, G. M., Porcelli, L. and Paradiso, A. (2008a). Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg. Med. Chem. 16, 362-373.
14. Colabufo, N. A., Berardi, F., Perrone, R., Rapposelli, S., Digiacomo, M., Vanni, M. and Balsamo, A. (2008b). Synthesis and biological evaluation of (Hetero) arylmethyloxyand arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents. J. Med. Chem. 51, 1415-1422.
15. Colabufo, N. A., Berardi, F., Perrone, R., Rapposelli, S., Digiacomo, M., Vanni, M. and Balsamo, A. (2008c). 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 Inhibitors: effect of different basic side-chains on their biological properties. J. Med. Chem. 51, 7602-7613.
16. Dantzig, A. H., Shepard, R. L., Law, K. L., Tabas, L., Pratt, S., Gillespie, J. S., Binkley, S. N., Kuhfeld, M. T., Starling, J. J. and Wrighton, S. A. (1999). Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 290, 854-862.
17. Das, U., Molnár, J., Baráth, Z., Bata, Z. and Dimmock, J. R. (2008). 1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis (benzylidene)4-oxopiperidines: a novel series of highly potent revertants of P-glycoprotein associated multidrug resistance. Bioorg. Med. Chem. Lett. 18, 3484-3487.
18. Dean, M., Rzhetsky, A. and Allikmets, R. (2001). The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166.
19. Demant, E. J., Sehested, M. and Jensen, P. B. (1990). A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug resistant tumor cells. Biochim. Biophys. Acta. 1055, 117-125.
20. Efferth, T. (2001). The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr. Mol. Med. 1, 45-65.
21. Fan, D., Beltran, P. J. and O'Brien, C. A. (1994). Reversal of multidrug resistance. In Reversal of Multidrug Resistance in Cancer (J. A. Kellen, Ed.), pp. 93-124. CRC Press, Boca Raton, FL.
22. Fong, W. F., Shen, X. L., Globisch, C., Wiese, M., Chen, G. Y., Zhu, G. Y., Yu, Z. L., Tse, A. K. W. and Hue, Y. J. (2008). Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells. Bioorg. Med. Chem. 16, 3694-3703.
23. Ford, J. M. and Hait, W. N. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42, 155-199.
24. Garcia, M., Jemal, A., Ward, E. M., Center, M. M., Hao, Y., Siegel, R. L. and Thun, M. J. (2007). Global Cancer Facts and Figures 2007. American Cancer Society, Atlanta, GA.
25. Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.
26. Gottesman, M. M., Fojo, T. and Bates, S. E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2, 48-58.
27. Gottesman, M. M. and Pastan, I. (1996). Drug resistance: alterations in drug uptake or extrusion. In Encyclopedia of Cancer (J. R. Bertino, Ed.) pp. 549-559. Academic, San Diego, CA.
28. Gruber, A., Bjorkholm, M., Brinch, L., Evensen, S., Gustavsson, B., Hedenus, M., Juliusson, G., Löfvenberg, E., Nesthus, I., Simonsson, B., Sjo, M., Stenke, L., Tangen, J. M., Tidefelt, U., Udén, A. M., Paul, C. and Liliemark, J. (2003). A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk. Res. 27, 323-328.
29. Häcker, H. G., de la Haye, A., Sterz, K., Schnakenburg, G., Wiese, M. and Gutschow, M. (2009a). Analogs of a 4-aminothieno[2,3-d]pyrimidine lead (QB13) as modulators of P-glycoprotein substrate specificity. Bioorg. Med. Chem. Lett. 19, 6102-6105.
30. Häcker, H. G., Leyers, S., Wiendlocha, J., Gütschow, M. and Wiese, M. (2009b). Aromatic 2-(Thio)ureidocarboxylic acids as a new family of modulators of multidrug resistanceassociated protein 1: synthesis, biological evaluation, and structure-activity relationships. J. Med. Chem. 52, 4586-4595.
31. Hao, X. Y., Widersten, M., Ridderström, M., Hellman, U. and Mannervik, B. (1994). Covariation of glutathione transferase expression and cytostatic drug resistance in HeLa cells: establishment of class Mu glutathione transferase M3-3 as the dominating isoenzyme. Biochem. J. 297, 59-67.
32. Henrich, C. J., Bokesch, H. R., Dean, M., Bates, S. E., Robey, R. W., Goncharova, E. I., Wilson, J. A. and McMahon, J. B. (2006). A high-throughput cell-based assay for inhibitors of ABCG2 activity. J. Biomol. Screen 11, 176-183.
33. Jin, J., Shahi, S., Kang, H. K., Van Veen, H. W. and Fan, T. P. (2006). Metabolism of ginsenosides as novel BCRP inhibitors. Biochem. Biophys. Res. Commun. 345, 1308-1314.
34. Jin, J., Wang, F. P., Wei, H. and Liu, G. (2005). Reversal of multidrug resistance of cancer through inhibition of Pglycoprotein by 5-bromotetrandrine. Cancer Chemother. Pharmacol. 55, 179-188.
35. Katayama, K., Masuyama, K., Yoshioka, S., Hasegawa, H., Mitsuhashi, J. and Sugimoto, Y. (2007). Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother. Pharmacol. 60, 789-797.
36. Kellen, J. A. (2003). The reversal of multidrug resistance: an update. J. Exp. Ther. Oncol. 3, 5-13.
37. Kim, D. H., Park, J. Y., Sohn, S. K., Lee, N. Y., Baek, J. H., Jeon, S. B., Kim, J. G., Suh, J. S., Do, Y. R. and Lee, K. B. (2006). Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int. J. Cancer 118, 2195-2201.
38. Kim, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., Wood, A. J. and Wilkinson, G. R. (1999). Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16, 408-414.
39. Krishna, R. and Mayer, L. D. (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283.
40. Krug, M., Voigt, B., Baumert, C., Lüpken, R., Molnár, J. and Hilgeroth, A. (2010). First biological evaluation of developed 3-benzyloxyfluorenes as novel class of MDR modulators. Eur. J. Med. Chem. 45, 2683-2688
41. Kühnle, M., Egger, M., Müller, C., Mahringer, A., Bernhardt, G., Fricker, G., König, B. and Buschauer, A. (2009). Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the P-Glycoprotein (ABCB1) modulator tariquidar. J. Med. Chem. 52, 1190-1197.
42. Leonard, G. D., Fojo, T. and Bates, S. E. (2003). The role of ABC transporters in clinical practice. Oncologist 8, 411-424.
43. Li, Y., Zhang, H. B. and Huang, W. L. (2008). Design and synthesis of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer. Bioorg. Med. Chem. Lett. 18, 3652-3655.
44. Limtrakul, P. (2007). Curcumin as chemosensitizer. Adv. Exp. Med. Biol. 595, 269-300.
45. Limtrakul, P., Chearwae, W., Shukla, S., Phisalphong, C. and Ambudkar, S. V. (2007a). Modulation of function of three ABC transporters, P-glycoprotein (ABCB1), mitoxanthrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell Biochem. 296, 85-95.
46. Limtrakul, P., Siwanon, S., Yodkeeree, S. and Duangrat, C. (2007b). Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells. Phytomedicine 14, 381-389.
47. Liscovitch, M. and Lavie, Y. (2002). Cancer multidrug resistance: a review of recent drug discovery research. Drugs 5, 349-355.
48. Liu, D. F., Li, Y. P., Ou, T. M., Huang, S. L., Gu, L. Q., Huang, M. and Huang, Z. S. (2009). Synthesis and antimultidrug resistance evaluation of icariin and its derivatives. Bioorg. Med. Chem. Lett. 19, 4237-4240.
49. Longley, D. B. and Johnston, P. G. (2005). Molecular mechanisms of drug resistance. J. Pathol. 205, 275-292.
50. Martelli, C., Coronnello, M., Dei, S., Manetti, D., Orlandi, F., Scapecchi, S., Romanelli, M. N., Salerno, M., Mini, E. and Teodori, E. (2010). Structure-activity relationships studies in a series of N,N-Bis(alkanol)amine aryl esters as P-Glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. J. Med. Chem. 53, 1755-1762.
51. Min, K. H., Xia, Y., Kim, E. K., Jin, Y. L., Kaur, N., Kim, E. S., Kim, D. K., Jung, H. Y., Choi, Y., Park, M. K., Min, Y. K., Lee, K. and Lee, K. (2009). A novel class of highly potent multidrug resistance reversal agents: Disubstituted adamantyl derivatives. Bioorg. Med. Chem. Lett. 19, 5376-5379.
52. Nakamura, M., Abe, Y., Katoh, Y., Oshika, Y., Hatanaka, H., Tsuchida, T., Yamazaki, H., Kijima, H., Inoue, H. and Ueyama, Y. (2000). A case of pulmonary adencarcinoma with overexpression of multidrug resistance associated protein and p53 aberration. Anticancer Res. 20, 1921-1925.
53. Newman, M. J., Rodarte, J. C., Benbatoul, K. D., Romano, S. J., Zhang, C., Krane, S., Moran, E. J., Uyeda, R. T., Dixon, R., Guns, E. S. and Mayer, L. D. (2000). Discovery and characterization of OC144-093, a novel inhibitor of P-glycoproteinmediated multidrug resistance. Cancer Res. 60, 2964-2972.
54. Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A. and Jain, R. K. (2001). Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. 98, 4628-4633.
55. Polgar, O. and Bates, S. E. (2004). ABC transporters in the balance: is there a role in multidrug resistance? Biochem. Soc. Trans. 33, 241-245.
56. Raad, I., Terreux, R., Richomme, P., Matera, E. L., Dumontet, C., Raynaud, J. and Guilet, D. (2006). Structureactivity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein. Bioorg. Med. Chem. 14, 6979-6987.
57. Romiti, N., Pellati, F., Nieri, P., Benvenuti, S., Adinolfi, B. and Chieli, E. (2008). P-glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal tubular cell lines. Planta Med. 74, 264-266.
58. Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P., Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L., Kraynak, M., Drengler, R., Stephenson, J. J., Harding, M. W. and Von Hoff, D. D. (1998). Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. 16, 2964-2976.
59. Rubio, G. J., Pinedo, H. M., Gazdar, A. F., Van Ark-Otte, J. and Giaccone, G. (1994). MRP gene assessment in human cancer, normal lung, and lung cancer cell lines. Proc. Am. Assoc. Cancer Res. 35, 206.
60. Shukla, S., Wu, C. P., and Ambudkar, S. V. (2008). Development of inhibitors of ATP-binding cassette drug transporters present status and challenges. Expert Opin. Drug Metab. Toxicol. 4, 205-223.
61. Skupien, K., Kostrzewa-Nowak, D., Oszmianski, J. and Tarasiuk, J. (2008). In vitro antileukemia activity of extracts from chokeberry (Aronia melanocarpa [Michx] Elliot) and mulberry (Morus alba L.) leaves against sensitive and multidrug resistant HL60 cells. Phytother. Res. 22, 689-694.
62. Takahashi, K., Kimura, Y., Nagata, K., Yamamoto, A., Matsuo, M. and Ueda, K. (2005). ABC proteins: key molecules for lipid homeostasis. Med. Mol. Morphol. 38, 2-12.
63. Theis, J. G., Chan, H. S., Greenberg, M. L., Malkin, D., Karaskov, V., Moncica, I., Koren, G. and Doyle, J. (2000). Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. Med. Pediatr. Oncol. 34, 242-249.
64. Thomas, H. and Coley, H. M. (2005). Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159-165.
65. Toppmeyer, D., Seidman, A. D., Pollak, M., Russell, C., Tkaczuk, K., Verma, S., Overmoyer, B., Garg, V., Ette, E., Harding, M. W. and Demetri, G. D. (2002). Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in 1580-1583. combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin. Cancer Res. 8, 670-678.
66. Van Zanden, J. J., De Mul, A., Wortelboer, H. M., Usta, M., van Bladeren, P. J., Ivonne, M. C., Rietjens, M., Nicole, H. and Cnubben, P. (2005). Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem. Pharmacol. 69, 1657-1665.
67. Viale, M., Cordazzo, C., Cosimelli, B., de Totero, D., Castagnola, P., Aiello, C., Severi, E., Petrillo, G., Cianfriglia, M. and Spinelli, D. (2009). Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: toward new candidates. J. Med. Chem. 52, 259-266.
68. Wada, M. (2006). Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response. Cancer Letter 234, 40-50.
69. Weiss, J., Sauer, A., Frank, A. and Unger, M. (2005). Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab. Dispos. 33, 1580-1583.
70. Wu, C. P., Calcagno, A. M., Hladky, S. B., Ambudkar, S. V. and Barrand, M. A. (2005). Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 272, 4725-4740.
71. Xia, Y., Min, K. H. and Lee, K. (2009). Synthesis and Biological Evaluation of Decursin, Prantschimgin and Their Derivatives. Bull. Korean Chem. Soc. 30, 43-48.
72. Yu, S. T., Chen, T. M., Tseng, S. Y. and Chen, Y. H. (2007). Tryotanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem. Biophys. Res. Commun. 358, 79-84.
73. Zaman, G. J. R., Versantvoort, C. H. M., Smit, J. J. M., Eijdems, E. W. H. M., De Haas, M., Smith, A. J., Broxterman, H. J., Mulder, N. H., De Vries, E. G. E., Baas, F. and Borst, P. (1993). Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 53, 1747-1750.